ECC5004

DRUG3 trials

Sponsors

Eccogene

Conditions

Type 2 Diabetes Mellitus

Phase 1

FTIH of ECC5004 in Healthy and Diabetic Participants

CompletedNCT05654831

EccogeneType 2 Diabetes Mellitus

Start: 2022-12-01End: 2023-11-01Updated: 2024-07-17

ECC5004 RBA FE Study in Healthy Participants

CompletedNCT06268145

EccogeneType 2 Diabetes Mellitus

Start: 2024-02-06End: 2024-03-29Updated: 2024-07-17

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

CompletedNCT06293742

EccogeneType 2 Diabetes Mellitus

Start: 2024-02-08End: 2024-04-15Updated: 2024-07-22

Related Papers

Non‐clinical and first‐in‐human characterization of <scp>ECC5004</scp> / <scp>AZD5004</scp> , a novel once‐daily, oral small‐molecule <scp>GLP</scp> ‐1 receptor agonist

Diabetes Obesity and Metabolism2024-11-0412 citations